2022

Crossed INR 48 billion of revenue
Incorporated Laurus Synthesis Pvt. Ltd & acquired assets of an API Unit in Vizag
Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited
Laurus Synthesis Inc USA is merged with Laurus Generics Inc USA.
Crossed INR 16 billion FDF Sales

2021

Incorporated Laurus Ingredients Pvt. Ltd. A Wholly Owned step down subsidiary of Laurus Synthesis Pvt. Ltd.
Acquisition of 72.55% stake in Richcore Life Sciences Pvt Ltd (Laurus Bio)
Laurus Labs acquires substantial minority stake in a CAR-T cell therapy company - ImmunoACT

2020

Incorporated Laurus Synthesis Pvt. Ltd
Acquired assets of an API Unit in Vizag
Acquired Aspen’s South Africa Subsidiary – Laurus Generics SA(PTY) Limited

2019

Unit 6 – EIR Received from USFDA
Entered into Strategic partnership with Global Fund for 3.5 years.
Executed a major tender order and delivered ahead of schedule
Executed highest on-time delivery in FDF orders.
Maiden EIR received for Unit 4

2018

Crossed INR 20 billion of revenue. Commenced commercial operations from Unit 4.
Incorporated a subsidiary in Germany.
Unit 2-Formulations, inspected by USFDA with Zero 483 observations.
Launched maiden FDF product Tenofovir in USA, Canada and emerging markets.
Certified as Great Place to Work for the year 2018.

2017

Successful USFDA inspection of Unit 1, 2 & 3 API manufacturing facilities with no critical observations. (Unit 2 has no 483 observations)
Successful WHO inspection of Units 1, 2 & 3
Successful BGV Hamburg (German Regulatory Authority) inspection of Unit 2 (FDF) with no critical or major observations

2016

Successful USFDA inspection of the kilo-lab facility at our R&D Centre
Received approval from BfArM Germany for Unit 2 at Vishakhapatnam
Crossed INR 15 billion in revenues
Filed first ANDA with the USFDA and first dossier with the WHO

2015

Commenced commercial operations at Unit 3, Visakhapatnam
Acquired 27% stake in Sriam Labs Private Limited, Hyderabad
Successful inspection by WHO, NIP Hungary and US FDA for Unit 1 and Unit 3 manufacturing sites

2014

Acquired 135 acres in Visakhapatnam for expansion
Received an investment of INR 3000 million from Bluewater
Commenced construction of Unit 2
Incorporated Laurus Inc. in Delaware, US as a wholly-owned subsidiary

2013

Crossed INR 10 billion in revenues
Received WHO approval for Unit-I

2012

Secured investment of INR 490 million from FIL Capital Management and FIP through primary investment and
Secondary acquisition of Aptuit’s majority stake along with additional investments by one of our promoters

2011

Received USFDA and KFDA certification for our R&D Centre
Received KFDA certification for Unit 1

2010

Received USFDA, TGA and UK MHRA certification for the Unit 1, Vishakhapatnam

2009

DSIR recognised our R&D Centre
Commercialised four nutritional fine chemicals
Launched first product in Europe
Entered into a license agreement with an international organisation and a multinational company to manufacture and sell our products in the ARV segment

2008

Filed our first-ever Drug Master File
Commenced operations at Unit-I
Supplied company’s first product to the US

2007

Set up API manufacturing facility Unit-I at Visakhapatnam
Secured investment from Aptuit Singapore of INR 1.02 billion
Executed manufacturing and services agreements with three multinational companies
Commenced operations at our R&D Centre

2006

Set up our R&D Centre at IKP, Knowledge Park, Hyderabad
Signed a term sheet with a leading Indian pharmaceutical company for oncology APIs
Filed our first patent application